Portfolio of Ebola vaccine. The vaccine candidate, called rVSV-EBOV, was originally developed by the Public Health Agency of Canada. It is currently being evaluated in phase-I clinical trials.
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.
Request a free trial